We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Strategic Alliance Will Promote Genetics Discovery Research

By LabMedica International staff writers
Posted on 18 Jan 2015
Print article
A major representative of the biotech industry will be collaborating with one of the United States' premiere research institutions in a 30 million USD strategic alliance to conduct genetics discovery research on the underlying causes of disease and to identify new treatment approaches.

The collaboration will enable the biotechnology company Biogen Idec (Cambridge, MA, USA) and Columbia University (New York, NY, USA) to investigate the genomes of patients showing unusual treatment responses or unique disease presentations and to explore the connections among genes, pathways, and disease processes. The ultimate goal will be to provide multiple qualified targets for new therapeutic approaches, increasing the potential for the development of new treatments.

To this end a sequencing and analysis facility and shared postdoctoral program will be established at Columbia University to support collaborative genetics studies. The new facility will have broad genetic research capabilities and the capacity to launch and complete whole-genome sequencing projects rapidly. It will allow for rapid population-scale DNA sequencing across a broad range of disease areas, focusing on diseases with significant unmet clinical need such as amyotrophic lateral sclerosis (ALS) and idiopathic pulmonary fibrosis.

"Our understanding of human genetics is rapidly expanding, and there is growing recognition that the elucidation of the genetic causes of disease will have a transformative effect on both patient care and drug development in many different diseases," said Dr. David Goldstein, founding director of the Institute for Genomic Medicine at Columbia University. "This collaboration marries the exceptional drug development expertise of Biogen with cutting-edge genomics expertise at Columbia University Medical Center. It will not only focus on target identification and validation at the early stages of drug development, but also facilitate genetically informed evaluation of treatments."

"Human genetic technologies and analytics have advanced to the point where they are becoming central to the discovery and development of new medicines," said Dr. Tim Harris, senior vice president, technology and translational sciences at Biogen Idec. "We are committed to working with leading institutions such as Columbia to advance basic genetic research and, by combining our unique strengths, accelerating the discovery of potential new treatments."

Related Links:

Biogen Idec
Columbia University


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Unit-Dose Packaging solution
HLX
New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
New
Thyroid ELISA Kit
AESKULISA a-TPO

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.